

Providing GLP-1 predictability while promoting long-term health

THE CHALLENGE

Rising demand and costs associated with GLP-1s

With over 40% of U.S. adults currently struggling with obesity,¹ the demand for GLP-1 medications is already substantial.

As more members seek out these treatments, the importance of implementing strategies to control costs continues to increase.

Notably, in the past year, drugs prescribed for weight management accounted for nearly half of the overall rise in drug spending.²

Evernorth's approach to managing GLP-1 spend

Evernorth EncircleRxSM addresses the needs of plan sponsors covering GLP-1s for cardiometabolic.

The solution helps members reach their goals by encouraging healthy habits and enabling plan sponsors to manage costs by ensuring those who need the medication the most have access.


HOW IT WORKS



Gives plan sponsors trend management and spend predictability.



Leverages medical documentation to manage utilization for members who need the medication the most.



Promotes personalized lifestyle modifications to encourage long-term wellness.



Prevents fraud, waste and abuse with GLP-1 anti-fraud protection.

ILLUSTRATIVE EXAMPLES OF IMPACT

For members, the impact of EncircleRx is clear:

7.7% average decrease in BMI³

2M+ pounds lost³

80% of members exceeded their program benchmarks in one year³

Plan sponsors have also experienced positive benefits, including:

11M+ people enrolled³

\$400M+ in client savings³

40% reduction in client trend when enrolled in the program³

[View EncircleRx 2025 annual report to dive deeper](#)

1. Centers for Disease Control and Prevention (CDC). "Adult Obesity Facts." www.cdc.gov/obesity/adult-obesity-facts. Page last reviewed: May 14, 2024. 2. Evernorth Health Services. "Pharmacy in Focus: Navigating the GLP-1 Conundrum." 2025. 3. Evernorth Commercial Book of Business data, 2025. Results may vary.